A shear-based assay for assessing plasma ADAMTS13 activity and inhibitors in patients with thrombotic thrombocytopenic purpura

Transfusion

Volumn 51, Issue 7, 2011, Pages 1580-1591

  Han, Yue ^a   Xiao, Juan ^a   Falls, Erica ^a   Zheng, X Long ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGAROSE; CHLORIDE ION; ENZYME INHIBITOR; GUANIDINE; SODIUM CHLORIDE; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; VON WILLEBRAND FACTOR CLEAVING PROTEINASE INHIBITOR; ZINC ION;

ADULT; AGED; ARTICLE; CHILD; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CORRELATION ANALYSIS; DENATURATION; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; HUMAN; HUMAN CELL; MALE; PEPTIDE ANALYSIS; PRESCHOOL CHILD; PROTEIN CLEAVAGE; PROTEIN DOMAIN; SENSITIVITY ANALYSIS; SHEAR STRESS; THROMBOTIC THROMBOCYTOPENIC PURPURA; WESTERN BLOTTING;

ADAM PROTEINS; CHLORIDES; HUMANS; PLATELET FUNCTION TESTS; PURPURA, THROMBOTIC THROMBOCYTOPENIC; SENSITIVITY AND SPECIFICITY; STRESS, MECHANICAL; VON WILLEBRAND FACTOR; ZINC;

EID: 79960154312     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2010.03020.x     Document Type: Article

References (49)

1. Furlan M, Robles R, Lammle B,. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 1996; 87: 4223-34. (Pubitemid 26152266)
2. Tsai HM,. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood 1996; 87: 4235-44.
3. Dong JF, Moake JL, Nolasco L, Bernardo A, Arceneaux W, Shrimpton CN, Schade AJ, McIntire LV, Fujikawa K, Lopez JA,. ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood 2002; 100: 4033-9. (Pubitemid 35396870)
4. Jin SY, Skipwith CG, Shang D, Zheng XL,. von Willebrand factor cleaved from endothelial cells by ADAMTS13 remains ultralarge in size. J Thromb Haemost 2009; 7: 1749-52.
5. Tsai HM, Sussman I, Nagel RL,. Shear stress enhances the proteolysis of von Willebrand factor in normal plasma. Blood 1994; 83: 2171-9. (Pubitemid 24112728)
6. Dong JF,. Cleavage of ultra-large von Willebrand factor by ADAMTS-13 under flow conditions. J Thromb Haemost 2005; 3: 1710-6.
7. Turner N, Nolasco L, Dong JF, Moake J,. ADAMTS-13 cleaves long von Willebrand factor multimeric strings anchored to endothelial cells in the absence of flow, platelets or conformation-altering chemicals. J Thromb Haemost 2009; 7: 229-32.
8. Zhang X, Halvorsen K, Zhang CZ, Wong WP, Springer TA,. Mechanoenzymatic cleavage of the ultralarge vascular protein von Willebrand factor. Science 2009; 324: 1330-4.
9. Siedlecki CA, Lestini BJ, Kottke-Marchant KK, Eppell SJ, Wilson DL, Marchant RE,. Shear-dependent changes in the three-dimensional structure of human von Willebrand factor. Blood 1996; 88: 2939-50. (Pubitemid 26357374)
10. Zhang Q, Zhou YF, Zhang CZ, Zhang X, Lu C, Springer TA,. Structural specializations of A2, a force-sensing domain in the ultralarge vascular protein von Willebrand factor. Proc Natl Acad Sci U S A 2009; 106: 9226-31.
11. Cao WJ, Krishnaswamy S, Camire RM, Lenting PJ, Zheng XL,. Factor VIII accelerates proteolytic cleavage of von Willebrand factor by ADAMTS13. Proc Natl Acad Sci U S A 2008; 105: 7416-21. (Pubitemid 351830032)
12. Shim K, Anderson PJ, Tuley EA, Wiswall E, Sadler JE,. Platelet-VWF complexes are preferred substrates of ADAMTS13 under fluid shear stress. Blood 2007; 111: 651-7.
13. Skipwith C, Cao W, Zheng XL,. Factor VIII and platelets synergistically accelerate cleavage of von Willebrand factor by ADAMTS13 under fluid shear stress. J Biol Chem 2010; 285: 28596-603.
14. Uemura M, Tatsumi K, Matsumoto M, Fujimoto M, Matsuyama T, Ishikawa M, Iwamoto TA, Mori T, Wanaka A, Fukui H, Fujimura Y,. Localization of ADAMTS13 to the stellate cells of human liver. Blood 2005; 106: 922-4. (Pubitemid 41076434)
15. Shang D, Zheng XW, Niiya M, Zheng XL,. Apical sorting of ADAMTS13 in vascular endothelial cells and Madin-Darby canine kidney cells depends on the CUB domains and their association with lipid rafts. Blood 2006; 108: 2207-15. (Pubitemid 44497501)
16. Suzuki M, Murata M, Matsubara Y, Uchida T, Ishihara H, Shibano T, Ashida S, Soejima K, Okada Y, Ikeda Y,. Detection of von Willebrand factor-cleaving protease (ADAMTS-13) in human platelets. Biochem Biophys Res Commun 2004; 313: 212-6. (Pubitemid 37524045)
17. Soejima K, Nakamura H, Hirashima M, Morikawa W, Nozaki C, Nakagaki T,. Analysis on the molecular species and concentration of circulating ADAMTS13 in blood. J Biochem (Tokyo) 2006; 139: 147-54. (Pubitemid 43258857)
18. Furlan M, Robles R, Solenthaler M, Wassmer M, Sandoz P, Lammle B,. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood 1997; 89: 3097-103. (Pubitemid 27229791)
19. Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B, Krause M, Scharrer I, Aumann V, Mittler U, Solenthaler M, Lämmle B,. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998; 339: 1578-84. (Pubitemid 28536132)
20. Kokame K, Matsumoto M, Soejima K, Yagi H, Ishizashi H, Funato M, Tamai H, Konno M, Kamide K, Kawano Y, Miyata T, Fujimura Y,. Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity. Proc Natl Acad Sci U S A 2002; 99: 11902-7. (Pubitemid 34994496)
21. Levy GG, Nichols WC, Lian EC, Foroud T, McClintick JN, McGee BM, Yang AY, Siemieniak DR, Stark KR, Gruppo R, Sarode R, Shurin SB, Chandrasekaran V, Stabler SP, Sabio H, Bouhassira EE, Upshaw JD Jr, Ginsburg D, Tsai HM,. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001; 413: 488-94. (Pubitemid 32938741)
22. Furlan M, Robles R, Solenthaler M, Lammle B,. Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura. Blood 1998; 91: 2839-46. (Pubitemid 28227534)
23. Tsai HM, Lian EC,. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998; 339: 1585-94. (Pubitemid 28536133)
24. Zheng XL, Richard KM, Goodnough LT, Sadler JE,. Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and non-idiopathic thrombotic thrombocytopenic purpura. Blood 2004; 103: 4043-9. (Pubitemid 38685342)
25. Arai S, Allan C, Streiff M, Hutchins GM, Vogelsang GB, Tsai HM,. Von Willebrand factor-cleaving protease activity and proteolysis of von Willebrand factor in bone marrow transplant-associated thrombotic microangiopathy. Hematol J 2001; 2: 292-9. (Pubitemid 32976372)
26. George JN, Sadler JE, Lammle B,. Platelets: thrombotic thrombocytopenic purpura. Hematology (Am Soc Hematol Educ Program) 2002; 1: 315-34.
27. Zheng XL,. ADAMTS13 testing: why bother? Blood 2010; 115: 1475-6.
28. Kokame K, Matsumoto M, Fujimura Y, Miyata T,. VWF73, a region from D1596 to R1668 of von Willebrand factor, provides a minimal substrate for ADAMTS-13. Blood 2004; 103: 607-12. (Pubitemid 38140094)
29. Kokame K, Nobe Y, Kokubo Y, Okayama A, Miyata T,. FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol 2005; 129: 93-100. (Pubitemid 40524057)
30. Zanardelli S, Chion AC, Groot E, Lenting PJ, McKinnon TA, Laffan MA, Tseng M, Lane DA,. A novel binding site for ADAMTS13 constitutively exposed on the surface of globular VWF. Blood 2009; 114: 2819-28.
31. Zhang P, Pan W, Rux AH, Sachais BS, Zheng XL,. The cooperative activity between the carboxyl-terminal TSP-1 repeats and the CUB domains of ADAMTS13 is crucial for recognition of von Willebrand factor under flow. Blood 2007; 110: 1887-94. (Pubitemid 47443901)
32. Tao Z, Peng Y, Nolasco L, Cal S, Lopez-Otin C, Li R, Moake JL, Lopez JA, Dong JF,. Role of the CUB-1 domain in docking ADAMTS-13 to unusually large von Willebrand factor in flowing blood. Blood 2005; 106: 4139-45.
33. Tao Z, Wang Y, Choi H, Bernardo A, Nishio K, Sadler JE, Lopez JA, Dong JF,. Cleavage of ultralarge multimers of von Willebrand factor by C-terminal-truncated mutants of ADAMTS-13 under flow. Blood 2005; 106: 141-3. (Pubitemid 40967185)
34. Raife TJ, Cao W, Atkinson BS, Bedell B, Montgomery RR, Lentz SR, Johnson GF, Zheng XL,. Leukocyte proteases cleave von Willebrand factor at or near the ADAMTS13 cleavage site. Blood 2009; 114: 1666-74.
35. Zhang L, Lawson HL, Harish VC, Huff JD, Knovich MA, Owen J,. Creation of a recombinant peptide substrate for fluorescence resonance energy transfer-based protease assays. Anal Biochem 2006; 358: 298-300. (Pubitemid 44573071)
36. Ai J, Smith P, Wang S, Zhang P, Zheng XL,. The proximal carboxyl-terminal domains of ADAMTS13 determine substrate specificity and are all required for cleavage of von Willebrand factor. J Biol Chem 2005; 280: 29428-34. (Pubitemid 41177015)
37. Zheng XL, Chung D, Takayama TK, Majerus EM, Sadler JE, Fujikawa K,. Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem 2001; 276: 41059-63.
38. De Cristofaro R, Lavoretano S, Lombardi R, Merati G, Romitelli F, Di SE, Mannucci PM,. Role of chloride ions in modulation of the interaction between von Willebrand factor and ADAMTS-13. J Biol Chem 2005; 280: 23295-302. (Pubitemid 40853242)
39. Zheng XL, Sadler JE,. Pathogenesis of thrombotic microangiopathies. Annu Rev Path Mech Dis 2008; 3: 249-77. (Pubitemid 351488282)
40. Vesely SK, George JN, Lammle B, Studt JD, Alberio L, El-Harake MA, Raskob GE,. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood 2003; 102: 60-8. (Pubitemid 36759636)
41. Veyradier A, Brivet F, Wolf M, Boyer-Neumann C, Obert B, Girma JP, Meyer D,. Total deficiency of specific von Willebrand factor-cleaving protease and recovery following plasma therapy in one patient with hemolytic-uremic syndrome. Hematol J 2001; 2: 352-4. (Pubitemid 32976379)
42. Feys HB, Anderson PJ, Vanhoorelbeke K, Majerus EM, Sadler JE,. Multi-step binding of ADAMTS13 to VWF. J Thromb Haemost 2009; 7: 2088-95.
43. Zanardelli S, Crawley JT, Chion CK, Lam JK, Preston RJ, Lane DA,. ADAMTS13 substrate recognition of von Willebrand factor A2 domain. J Biol Chem 2006; 281: 1555-63.
44. Iacopino P, Pucci G, Arcese W, Bosi A, Falda M, Locatelli F, Marenco P, Miniero R, Morabito F, Rossetti F, Sica S, Uderzo C, Bacigalupo A,. Severe thrombotic microangiopathy: an infrequent complication of bone marrow transplantation. Gruppo Italiano Trapianto Midollo Osseo (GITMO). Bone Marrow Transplant 1999; 24: 47-51. (Pubitemid 29346604)
45. Anderson PJ, Kokame K, Sadler JE,. Zinc and calcium ions cooperatively modulate ADAMTS13 activity. J Biol Chem 2006; 281: 850-7.
46. Hovinga JA, Vesely SK, Terrell DR, Lammle B, George JN,. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood 2010; 115: 1500-11.
47. Shelat SG, Smith AG, Ai J, Zheng XL,. Inhibitory autoantibodies against ADAMTS-13 in patients with thrombotic thrombocytopenic purpura bind ADAMTS-13 protease and may accelerate its clearance in vivo. J Thromb Haemost 2006; 4: 1707-17. (Pubitemid 44144797)
48. Eckmann CM, De Laaf RT, Van Keulen JM, Van Mourik JA, De Laat B,. Bilirubin oxidase as a solution for the interference of hyperbilirubinemia with ADAMTS-13 activity measurement by FRETS-VWF73 assay. J Thromb Haemost 2007; 5: 1330-1. (Pubitemid 46902141)
49. Meyer SC, Sulzer I, Lammle B, Kremer Hovinga JA,. Hyperbilirubinemia interferes with ADAMTS-13 activity measurement by FRETS-VWF73 assay: diagnostic relevance in patients suffering from acute thrombotic microangiopathies. J Thromb Haemost 2007; 5: 866-7. (Pubitemid 46563591)